Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 16/20 | 0.56 |
| ▸ | MMP1 | P03956 | 3/20 | 0.56 |
| ▸ | MMP7 | P09237 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 12/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9289897 | 0.95 | MMP3 (0.58) | MMP3MMP1MMP7MMP2 | |
| SCHEMBL7763668 | 0.92 | MMP3 (0.54) | MMP3MMP1MMP7MMP2 | |
| SCHEMBL7764977 | 0.90 | MMP3 (0.59) | MMP3MMP1MMP7MMP2MMP9 | |
| SCHEMBL7758535 | 0.90 | MMP3 (0.59) | MMP3MMP1MMP7MMP2MMP9 | |
| SCHEMBL7762087 | 0.89 | MMP3 (0.52) | MMP3MMP1MMP7MMP2 | |
| SCHEMBL7763782 | 0.88 | MMP3 (0.51) | MMP3MMP1MMP7MMP2MMP9 | |
| SCHEMBL7763701 | 0.86 | MMP3 (0.50) | MMP3MMP1MMP7MMP2MMP9 | |
| SCHEMBL7758445 | 0.85 | MMP2 (0.52) | MMP3MMP1MMP7MMP2MMP9 | |
| SCHEMBL7763176 | 0.85 | MMP3 (0.53) | MMP3MMP1MMP7MMP2MMP9 | |
| SCHEMBL7763812 | 0.85 | MMP3 (0.54) | MMP3MMP1MMP7MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |